Results 111 to 120 of about 18,181 (226)

Recommendations on biosimilar low-molecular-weight heparins.

open access: yes, 2009
International audienceBased on the results of large clinical trials, several low-molecular-weight heparins (LMWHs) have been approved for prophylaxis and the treatment of venous and arterial thromboembolism.
Harenberg, J.   +35 more
core   +1 more source

Switching From Originator to Biosimilar Infliximab in Pediatric Inflammatory Bowel Disease: A Systematic Review and Meta‐Analysis

open access: yesJCC Plus, Volume 1, Issue 6, November 2026.
In this meta‐analysis of eight studies (508 children with inflammatory bowel disease), switching from originator to biosimilar infliximab preserved clinical remission, drug exposure, and immunogenicity, with high treatment persistence and no signal of efficacy or safety loss. Biosimilar switching appears a safe, effective option in pediatric IBD.
Douglas Amaral da Silva Menegazzo Miotto   +4 more
wiley   +1 more source

Switching Patients from Originator to Biosimilar Medications in Rheumatoid Arthritis: Limiting the ‘Nocebo’ Effect

open access: yes, 2017
Biosimilars have been available in Europe since 2006, and biosimilars of monoclonal antibodies since 2013, and are now a widespread clinical reality.
Biogen
core  

Proactive therapeutic drug monitoring of infliximab leads to treatment durability in paediatric Crohn's disease: A single‐centre Australian experience

open access: yesJPGN Reports, Volume 7, Issue 4, Page 536-543, November 2026.
Abstract Objectives To evaluate the durability and predictors of loss of response of infliximab (IFX) over 2 years in paediatric Crohn's disease (CD) utilizing a proactive therapeutic drug monitoring (TDM) strategy. Methods A retrospective, single‐centre cohort study was conducted at The Children's Hospital at Westmead (CHW), Australia, from January ...
Cher Wei Chuah   +9 more
wiley   +1 more source

Characteristics of trials comparing biosimilar and reference insulins.

open access: yes, 2018
Characteristics of trials comparing biosimilar and reference insulins.
Carolyn Tieu (5117252)   +4 more
core   +1 more source

Biosimilars [PDF]

open access: yesProceedings of the National Academy of Sciences, 2015
G.-R. Burmester, U. Müller-Ladner
openaire   +4 more sources

Superior Clinical and Economic Value of IL‐23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis

open access: yesInternational Journal of Dermatology, Volume 65, Issue 11, Page 2362-2370, November 2026.
A bicentric retrospective real‐world study (N = 616) comparing IL‐23 inhibitors (guselkumab, risankizumab, tildrakizumab) with adalimumab biosimilars in moderate‐to‐severe plaque psoriasis. It presents PASI90 response at Weeks 16 and 52, NNT, and cost‐effectiveness (incremental cost per responder, CE plane, CEAC/CEAF).
Gennaro Marco Falco   +13 more
wiley   +1 more source

FDA Approves Trastuzumab Biosimilar

open access: yes, 2018
On December 1, the FDA approved a second cancer biosimilar, trastuzumab-dkst. The drug was approved to treat patients with HER2-positive breast and metastatic stomach cancers.

core   +1 more source

The cost-effectiveness of biologic/targeted synthetic/biosimilar disease modifying antirheumatic drugs: a systematic review.

open access: yes, 2021
OBJECTIVES: The clinical efficacy of biologic/targeted synthetic/biosimilar disease modifying antirheumatic drugs (b/ts/biosimilar DMARDs) in treating inflammatory arthritis is well documented, while the economic performance of these agents remains vague.
Peng, K   +6 more
core  

Home - About - Disclaimer - Privacy